Sun Pharmaceutical Industries Ltd. is talking with advisers about a possible bid for New York-listed wellness company Organon & Co., according to people familiar with the matter.
India’s biggest pharmaceutical company, with a market capitalisation of $43 billion, has held preliminary discussions with global lenders to arrange financing for a possible deal, the people said, asking not to be identified because the information is private.
Considerations are preliminary and Sun Pharma may decide to not pursue a bid, the people said. There could also be other suitors for Organon, they said.
The Economic Times reported Sun Pharma’s interest in Organon earlier this week, prompting an 8 per cent rally in the US-based company’s shares on Tuesday. Even so, Organon has fallen 40 per cent in the past 12 months, giving it a market value of about $2.5 billion.
Representatives for Sun Pharma and Organon didn’t respond to requests for comment.
Organon focuses on improving women’s health with a portfolio focused on areas such as breast cancer, fertility and menopause, according to its website.
More stories like this are available on bloomberg.com
Published on January 22, 2026
